Joint venture aims to develop up to 10 new cell and gene therapy products targeting areas with high unmet medical needs.
AstraZeneca Finalizes Equity Investment, Research Collaboration with Cellectis
You May Also Like
Global Launch Strategies in the Current Political Climate
February 19, 2025
FDA Approves Samsung Bioepis Biosimilars Ospomyv and Xbryk
February 19, 2025
Navigating Distrust: Pharma in the Age of Social Media
February 18, 2025
+ There are no comments
Add yours